Interleukin-28A Induces Epithelial Barrier Dysfunction in CD Patient-derived Intestinal Organoids

Crohn’s disease patient-derived intestinal organoids were characterized by differentiation gene markers and then exposed to TNF-α, IFN-γ, IL-1β or LPS, or IL-28A with or without GLPG0634.
[American Journal of Physiology-Gastrointestinal and Liver Physiology]
Xu, P., Becker, H., Elizalde, M., Pierik, M., Masclee, A. A. M., & Jonkers, D. M. A. E. (2021). Interleukin-28A Induces Epithelial Barrier Dysfunction in CD Patient-derived Intestinal Organoids. American Journal of Physiology-Gastrointestinal and Liver Physiology. https://doi.org/10.1152/ajpgi.00064.2020 Cite
Abstract
Bookmark

No account yet? Register

0
Share

From Inflammation to Colitis-Associated Colorectal Cancer in Inflammatory Bowel Disease: Pathogenesis and Impact of Current Therapies

Scientists present an overview of the current knowledge of colitis-associated cancer (CAC) in inflammatory bowel disease (IBD) patients, focusing on the role of inflammation in the pathogenesis of CAC and the potential for IBD drugs to interfere with the process of carcinogenesis by reducing the inflammatory process or by modulating pathways directly involved in carcinogenesis.
[Digestive and Liver Disease]
Abstract
Bookmark

No account yet? Register

0
Share

The Roles and Functions of Paneth Cells in Crohn’s Disease: A Critical Review

Paneth cells are located at the base of small intestinal crypts and secrete the α‐defensins, human α‐defensin 5 and human α‐defensin 6 in response to bacterial, cholinergic and other stimuli.
[Cell Proliferation]
Full Article
Bookmark

No account yet? Register

0
Share

Monocytes from Infliximab-Resistant Patients with Crohn’s Disease Exhibit a Disordered Cytokine Profile

Investigators compared the inflammatory phenotype of monocytes from Crohn’s disease patients, who responded or non-responded to infliximab. Under basal conditions, the mRNA for the cytokines TNFα, IL-23, IL-1β and the chemokines CXCL8/IL-8, CCL5/RANTES and CCL2/MCP-1 was up-regulated in monocytes from non-responders than responders.
[Scientific Reports]
Full Article
Bookmark

No account yet? Register

0
Share

Mylan and Fujifilm Kyowa Kirin Biologics Announce US FDA Approval of Hulio® (adalimumab-fkjp)

Mylan N.V. and Fujifilm Kyowa Kirin Biologics Co., Ltd. announced that the FDA has approved Hulio® for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis, in both prefilled syringe and auto-injector presentations.
[Mylan]
Press Release
Bookmark

No account yet? Register

+1
Share

AXL Is a Potential Target for the Treatment of Intestinal Fibrosis

This study demonstrated that inhibition of AXL signaling with the small molecule inhibitor BGB324 abrogated both matrix-stiffness and transforming growth factor beta–induced fibrogenesis in human colonic myofibroblasts.
[Inflammatory Bowel Diseases]
Abstract
Bookmark

No account yet? Register

+1
Share

UCB and Ferring Pharmaceuticals Announce Co-promotion of Cimzia® (Certolizumab Pegol) for the Treatment of Adults with Moderate to Severe Crohn’s Disease

UCB and Ferring Pharmaceuticals Inc. announced they have entered into a co-promotion agreement to commercialize the prefilled syringe formulation of CIMZIA® in the United States, specifically for the treatment of Crohn’s disease.
[UCB]
Press Release
Bookmark

No account yet? Register

0
Share

Impaired Estrogen Signaling Underlies Regulatory T Cell Loss-of-Function in the Chronically Inflamed Intestine

Using a strain of congenic SAMP mice engineered to lack global expression of ERβ, investigators observed dramatic, female-specific exacerbation of intestinal inflammation accompanied by significant reductions in intestinal regulatory T cell frequency and function.
[Proceedings of the National Academy of Sciences of the United States of America]
Abstract
Bookmark

No account yet? Register

0
Share

Celltrion Healthcare Receives Positive CHMP Opinion for an Additional Five Indications for Remsima® SC Including for Use in Inflammatory Bowel Disease

Celltrion Healthcare announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended expanding the existing marketing authorisation for the subcutaneous formulation of Remsima® in an additional five indications: for the treatment of patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.
[Celltrion]
Press Release
Bookmark

No account yet? Register

0
Share

Difference in Presence and Number of CD83+ Dendritic Cells in Patients with Ulcerative Colitis and Crohn’s Disease

There were 154 subjects included in this study: 60 with ulcerative colitis, 19 with Crohn’s disease and 75 in the control group. Colonic biopsy was performed in all subjects. Specimens were incubated with a primary anti-CD83 antibody.
[Scientific Reports]
Full Article
Bookmark

No account yet? Register

0
Share
Share